Analysts call $310 CSL target price in new report
SYDNEY: Biotech company CSL was upgraded to ‘buy’ by analysts at Citi Group ...
To read the full story...SUBSCRIBE NOWExisting Subscribers Login Below:
Log In
FEATURED
Star Entertainment announces late change in substantial shareholding
PointsBet spars with BlueBet over funding and synergies
Flagstaff advising PointsBet on latest share market frolic
Pointsbet surges on Betr approach as speculators take price punt
Matt Trip’s Bet revs-up gaming rival $360m Pointsbet offer